Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
about
Molecular Insight into Substrate Recognition and Catalysis of Baeyer–Villiger Monooxygenase MtmOIV, the Key Frame-Modifying Enzyme in the Biosynthesis of Anticancer Agent MithramycinThe crucial role of divalent metal ions in the DNA-acting efficacy and inhibition of the transcription of dimeric chromomycin A3The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP.Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application.Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer.Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK).Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity.A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis.Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomicsFermented mistletoe extract as a multimodal antitumoral agent in gliomas.The specificity protein factor Sp1 mediates transcriptional regulation of P2X7 receptors in the nervous system.Semi-synthetic mithramycin SA derivatives with improved anticancer activity.Starvation after Cobalt-60 γ-Ray Radiation Enhances Metastasis in U251 Glioma Cells by Regulating the Transcription Factor SP1.Specific protein 1 depletion attenuates glucose uptake and proliferation of human glioma cells by regulating GLUT3 expression.Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells.Sp1 and the 'hallmarks of cancer'.Identification of differentially expressed genes regulated by transcription factors in glioblastomas by bioinformatics analysisSmall molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.The "go or grow" potential of gliomas is linked to the neuropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress.The impact of high co-expression of Sp1 and HIF1α on prognosis of patients with hepatocellular cancer.Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase.Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux.Extracellular vesicles from human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect against renal ischemia/reperfusion injury via delivering specificity protein (SP1) and transcriptional activating of sphingosine kRepair gene O6 -methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation.MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma.Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 promotes lung adenocarcinoma by directly interacting with specificity protein 1.
P2860
Q27679838-B471256D-19D7-4CC8-A050-CC366C5D1C7BQ28483713-C1F727AC-2B36-4EB9-BBDD-89C6C2C77696Q34294301-848235DC-82CD-4688-B2DD-9DB291C8C5FEQ34302162-453003A4-A243-41DD-8DD9-374999BF516DQ34561618-2EEDCBA7-DD98-4A5C-A591-D760D137C2C3Q35027553-A127919B-45AA-4BF5-8C52-D1CF6ECBB82DQ35556943-B23DB3DD-27AA-4BDE-9B8E-09A84A743262Q36090660-9035451E-B330-4E51-97E4-CCCD1D68CF28Q36104523-CBE636D3-1C11-4AEA-B272-6941AA29A9B3Q36361068-2DB6304F-DA22-400D-B78D-B8EF04196157Q36492899-29BC1626-3F0A-4AD4-B583-53E5EEE034D1Q36794596-5B14E4D8-6877-4C64-BC31-704BE6CD1FECQ36846833-E82C8A52-D651-4B7D-8E60-FB2370B2F1E4Q37001138-F19A7924-D0BF-4E0A-A43B-5447C639AEEBQ37096690-1C5BE27E-EF7E-4069-A495-A6915167B5B1Q38267908-1B5E916A-5DD6-4502-BFB0-C2DA7CEE39B9Q38468970-108D10DF-477B-4669-A9D0-2361E70481A4Q39369722-0D9D45C2-9E48-4181-83A2-5273121925CEQ39411316-341A83A9-61BD-4E90-8F70-628CC6472C50Q40680671-D30C67CB-FA05-4C9B-9000-718D467BCB42Q41453815-38B1867E-D382-4E8F-BAB1-77BC81DEEBB0Q42004283-C146AD2C-D6BB-4B74-95E2-EC55AABBD3FAQ47300876-CA6A687C-4E33-4DE3-965C-25BB09616135Q48256976-E8C0077A-8EEC-46D5-9E5F-E31E0A00B5A1Q50894719-A330B1D0-8AD1-4334-BE48-B02C6A479503Q55019234-4D2DB026-32B2-4971-8DCE-3874DDA8C572
P2860
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
@en
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
@nl
type
label
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
@en
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
@nl
prefLabel
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
@en
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
@nl
P2093
P2860
P1476
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.
@en
P2093
Björn Silkenstedt
Janina Seznec
Ulrike Naumann
P2860
P2888
P304
P356
10.1007/S11060-010-0266-X
P577
2010-06-17T00:00:00Z